New York University Langone Medical Center
Laura and Isaac Perlmutter Cancer Center
New York, NY
Accepting patients
EXCALIBER - Maintenance
Phase 3 Clinical Trial Comparing Iberdomide VS Lenalidomide as Maintenance Therapy Following Autologous Stem Cell Transplant in Participants with Newly Diagnosed Multiple Myeloma
- CELMoD
- Randomization
- Post-Autologous Stem Cell Transplant
- Phase 3
Accepting patients
MajesTEC-7
A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
- Has results
Accepting patients
TRIlogy-4
A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti CD38 Antibody
- Trispecific Antibody
- T Cell Engager (TCE)
- GPRC5D
- CD3
- BCMA
- Randomization
- Phase 3
Accepting patients
LINKER-MM4
Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple Myeloma
- Bispecific Antibody
- BCMA
- Phase 1/2
- Has results
Accepting patients
SIM0500
A Phase I First-in-human, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, A Humanized GPRC5D-BCMA-CD3 Tri-specific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
- Trispecific Antibody
- BCMA
- GPRC5D
- Phase 1
Accepting patients
DURGA-2
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma
- CAR T Cell
- CD19
- BCMA
- High Risk
- Phase 1